跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

N8162

Sigma-Aldrich

NIDA-41020

≥97% (HPLC), solid

别名:

1-(2,4-Dichlorophenyl)-5-(4-methoxyphenyl)-4-methyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C23H24Cl2N4O2
CAS号:
502486-89-7
分子量:
459.37
MDL编号:
MFCD08277026
UNSPSC代码:
12352200
PubChem化学物质编号:
329818682
NACRES:
NA.77

质量水平

100

方案

≥97% (HPLC)

表单

solid

颜色

off-white

溶解性

DMSO: ~16 mg/mL
H2O: insoluble

储存温度

2-8°C

SMILES字符串

COc1ccc(cc1)-c2c(C)c(nn2-c3ccc(Cl)cc3Cl)C(=O)NN4CCCCC4

InChI

1S/C23H24Cl2N4O2/c1-15-21(23(30)27-28-12-4-3-5-13-28)26-29(20-11-8-17(24)14-19(20)25)22(15)16-6-9-18(31-2)10-7-16/h6-11,14H,3-5,12-13H2,1-2H3,(H,27,30)

InChI key

KWDBQJRWPWTGPF-UHFFFAOYSA-N

生化/生理作用

NIDA-41020 is a CB1 cannabinoid receptor antagonist. NIDA-41020 is structurally similar to Rimonabant, which is currently in clinical development. NIDA-41020 is less lipophilic; developed at NIDA as a potential radioligand for CB1 receptors, Ki = 4.1 nM [in comparison AM 251, AM 281, SR 141716 (Rimonabant) have Ki of 0.6, 4.5 and 1.8 nM respectively].
NIDA-41020 is a CB1 cannabinoid receptor antagonist.

象形图

Skull and crossbones
GHS06

警示用语：

Danger

危险分类

Acute Tox. 2 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
011M4615V
115K4600

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Reeti Katoch-Rouse et al.
Journal of medicinal chemistry, 46(4), 642-645 (2003-02-07)
Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophilic compounds that exhibit very high
Jos H M Lange et al.
Drug discovery today, 10(10), 693-702 (2005-05-18)
The proven clinical efficacy of the CB(1) cannabinoid receptor antagonist rimonabant in both obesity and smoking cessation and its therapeutic potential in other disorders has given a tremendous impetus to the discovery of novel CB(1) antagonists. The number of disclosed

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门